Enza mix.

Indications for enzalutamide are ever expanding. This practical phase 2 trial ponders if there is any advantage to adding it to definitive radiation and androgen deprivation therapy (ADT) for high-risk prostate cancer. Radiation consisted of 45 Gy / 25 external beam to the pelvis (with simultaneous or sequential boost of 55 - 59.4 Gy to any gross nodes) followed by a high-dose rate brachytherapy boost of 15 Gy x1. The ADT consisted of 24 months of leuprolide with the addition of enzalutamide. There were only 11 patients who initiated treatment on trial, and adverse events were as expected. At 36 months, only one patient had experienced a biochemical recurrence, and he discontinued his ADT + enzalutamide early due to side effects. | Shee, Adv Radiat Oncol 2022


Popular Posts